课题基金 / 基金详情

Core--Lipids and Chronic Diseases

Core--Lipids and Chronic Diseases
核心--血脂与慢性病
批准号:
6732571
负责人:
RONALD M KRAUSS
金额:
$5.09万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-01-15 至 2007-12-31

项目摘要

项目成果

RONALD M KRAUSS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Overall Objectives of the Lipids and Chronic Diseases Research Core: High intakes of lipids and calories are associated with increased incidence and severity of chronic diseases including diabetes, obesity, certain cancers, and cardiovascular diseases (CVD). As a consequence of high intakes of fat, lipid metabolism is altered and contributes to the initiation and development of disease processes. The disease process in turn alters metabolism further contributing to additional complications. One of the most prevalent risk factors and targets of therapy for these diseases is dyslipidemias, which are known to be affected by diet. Minority populations have disproportionately high incidences and morbidities of all chronic diseases and specifically prostate cancer (Powell and Meyskens 2001), diabetes (Kamel, Rodriguez-Saldana et al. 1999), asthma (Strunk, Ford et al. 2002), obesity (including childhood obesity (Crawford, Story et al. 2001), and cardiovascular diseases (CVD). Observations from the largest survey of dietary habits and health status in the U.S., the Third National Health and Nutrition Examination Survey (NHANES), have established that older black and Mexican American women and black men were at greatest risk for CVD (Winkleby, Kraemer et al. 1998; Sundquist, Winkleby et al. 2001), paralleling the heightened risk of CVD among younger ethnic minority populations (Winkleby, Robinson et al. 1999). Multiple CVD risk factors, including plasma lipids as well as dietary fat, obesity, hypertension, and diabetes, contribute to these ethnic differences.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pharmacogenomics of Statin Therapy
Pharmacogenomics of Statin Therapy
Pharmacogenomics of Statin Therapy
Genetic Etiology of Cancer Drug Response
海外基金